✦ LIBER ✦

Product R&D for neglected diseases

✍ Scribed by Ridley, Robert G.

Book ID: 110033637
Publisher: Nature Publishing Group
Year: 2003
Tongue: English
Weight: 113 KB
Volume: 4
Category: Article
ISSN: 1469-221X
DOI: 10.1038/sj.embor.embor858

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Financing R&D for neglected diseases

✍ Herrling, Paul L. 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 96 KB

ChemInform Abstract: Natural Products fo

ChemInform Abstract: Natural Products for Neglected Diseases

✍ Jean-Robert Ioset 📂 Article 📅 2008 🏛 John Wiley and Sons ⚖ 15 KB 👁 1 views

$25 million for R & D

✍ Gwynne, Peter 📂 Article 📅 1991 🏛 Nature Publishing Group 🌐 English ⚖ 142 KB

Leveraging biotech's drug discovery expe

Leveraging biotech's drug discovery expertise for neglected diseases

✍ Lowell, Joanna E; Earl, Christopher D 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 355 KB

Drug discovery and development for negle

Drug discovery and development for neglected parasitic diseases

✍ Renslo, Adam R; McKerrow, James H 📂 Article 📅 2006 🏛 Nature Publishing Group 🌐 English ⚖ 314 KB

Orphan drug legislation: lessons for neg

Orphan drug legislation: lessons for neglected tropical diseases

✍ Stefano Villa; Amelia Compagni; Michael R. Reich 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB

## Abstract In the last 20 years, orphan drug legislation (ODL) has been adopted in several countries around the world (USA, Japan, Australia, and the European Union) and has successfully promoted R&D investments to develop new pharmaceutical products for the treatment of rare diseases. Without the

Product R&#38;D for neglected diseases

Product R&D for neglected diseases